Wells Fargo Reiterates Equal Weight Rating on Horizon Therapeutics (HZNP) as Potential FTC Lawsuit Increases Risk to Amgen (AMGN) Deal

Wells Fargo analyst Derek Archila reiterated an Equal Weight rating on Horizon Therapeutics (NASDAQ: HZNP) after Bloomberg News reported that the federal trade commission (FTC) is expected to bring a lawsuit to block AMGN-HZNP proposed merger.

"Our look at past instances of FTC lawsuits make us see risk to AMGN-HZNP deal. AMGN investors in general did not like this deal, so they might be indifferent. We see FV of AMGN without deal at $255/sh while HZNP could be $80-90/sh without this deal."

For an analyst ratings summary and ratings history on Horizon Therapeutics click here. For more ratings news on Horizon Therapeutics click here.

Shares of Horizon Therapeutics closed at $112.25 yesterday.

You May Also Be Interested In

• Diana Shipping withdraws bid to acquire Genco Shipping
• New Street Research Upgrades Micron Technology (MU) to Buy
• Proficient Auto Logistics closes Hansen & Adkins acquisition